Acute Porphyria Drug Database

C09AA02 - Enalapril
Not porphyrinogenic
NP

Rationale
No evidence of CYP-dependent metabolism. Older references indicate that an attack has been associated with enalapril, but newer clinical data question the causality of this observation. Porhyrin accumulation has been found in a model with primary chick embryo liver cells. These findings were at high supratherapeutic concentrations, and seem less relevant. The magnitude of uneventful clinical experience, including a small open study with 15 AIP patients, points to non-porphyrinogenicity. Risk for gastrointestinal adverse events in the form of nausea and diarrhoea motivates vigilance against insufficient intake of food, especially of carbohydrate.
Chemical description
Derivative of the amino acid L-proline
Therapeutic characteristics
ACE-inhibitor. A very common side effect that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack is nausea. Common side effects are diarrhoea, abdominal pain, tachycardia and fatigue.
Metabolism and pharmacokinetics
Hydrolyzed to enalaprilate, otherwise not metabolized. CYP450 is not involved in the hydrolysis of enalapril.
Preclinical data
Studies with primary chick embryo liver cells treated with desferrioxamine simulating conditions found in porphyric patients showed that enalapril substantially increased porphyrin accumulation when given in very high concentrations (Lambrecht RW et al. 1999). According to the authors patients with acute porphyrias may be at greater risk for developing porphyric attacks when treated with enalapril, compared to captopril or lisinopril. The therapeutic plasma concentrations of enalapril (as enalaprilate) are normally under 0.05 microgram/ml (0.13 microM). The concentrations at which Lambrecht et al found porphyrin accumulation in their experiment were more than 2000 times higher.
Personal communication
Andersson, patient report (n=6): tolerated.
Published experience
Short term use of enalapril did not induce a clinical or biochemical attack in 15 AIP patients. This was demonstrated by clinical examination and unaltered Watson Schwartz test (12-hour for 72 hours after dosing), thus establishing its safety (Bandyopadhyay M et al, 2002). In a review article enalapril is listed as being associated with attacks (Gorchein A, 1997) while referring to the Oxford Textbook of Medicine, Third Edition, as well as to the British National Formulary. In subsequent editions of these sources the editors no longer list enalapril as a porphyrinogenic drug. Other sources like Martindale and the Australian webside most likely refer to the same observation(s). In the light of the findings of Bandyopadhyay et al the earlier observation(s) may lack causality.
IPNet drug reports
Uneventful use reported in 44 patients with acute porphyria.

References

  1. Scientific articles
  2. Bandyopadhyay M, Gupta BK, Panwar RB, Kabra PK, Kaushik AN, Chadda VS. A study of 24-hour ambulatory blood pressure monitoring in cases of intermittent acute porphyria with hypertension: Special reference to safety and efficacy of angiotensin-converting enzyme inhibitor (Enalapril) therapy [2]. Indian Heart Journal 2002; 54(6):734. PMID 12674196. #4410
  3. Gorchein A. Drug treatment in acute porphyria. British Journal of Clinical Pharmacology 1997; 44(5):427-434. PMID 9088595. #1232
  4. Lambrecht RW, Gildemeister OS, Williams A, Pepe JA, Tortorelli KD, Bonkovsky HL. Effects of selected antihypertensives and analgesics on hepatic porphyrin accumulation accumulation. Implications for clinical porphyria. Biochemical Pharmacology 1999; 58(5):887-896. PMID 10449201. #4411

Similar drugs
Explore alternative drugs in similar therapeutic classes C09A / C09AA or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙